Allergan Plc (AGN)

164.26
NYSE : Health Technology
Prev Close 166.08
Day Low/High 164.21 / 166.21
52 Wk Low/High 114.27 / 197.00
Avg Volume 3.91M
Exchange NYSE
Shares Outstanding 327.82M
Market Cap 54.45B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.76%)
Allergan Reports First Quarter 2019 Financial Results

Allergan Reports First Quarter 2019 Financial Results

-- Q1 2019 GAAP Net Revenues of $3.60 Billion --

Aegon Calls USD 500 Million In Perpetual Capital Securities

Aegon Calls USD 500 Million In Perpetual Capital Securities

Aegon today announces that it is exercising its right to redeem the USD 500 million perpetual capital securities with a coupon of 6.

Allergan Expected to Earn $3.55 a Share

Allergan Expected to Earn $3.55 a Share

Allergan revenue expected to fall 3.7% to $3.5 billion.

Medicines360 And Allergan Present Six-Year Clinical Data From Largest Ongoing Phase 3 Study Of An Intrauterine System In The U.S.

Medicines360 And Allergan Present Six-Year Clinical Data From Largest Ongoing Phase 3 Study Of An Intrauterine System In The U.S.

Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting

Status Quo Great for Stocks: Cramer's 'Mad Money' Recap (Friday 5/3/19)

Status Quo Great for Stocks: Cramer's 'Mad Money' Recap (Friday 5/3/19)

Jim Cramer says the economy is just right for stocks, but he's still worried about IPO froth. Here's your game plan for next week.

Allergan Declares Second Quarter 2019 Cash Dividend Of $0.74 Per Ordinary Share

Allergan Declares Second Quarter 2019 Cash Dividend Of $0.74 Per Ordinary Share

- Dividend to be Paid on June 14, 2019 -

Allergan To Present Two Podium Presentations On Bimatoprost Sustained-Release (SR) At The American Society Of Cataract And Refractive Surgery (ASCRS) Annual Meeting

Allergan To Present Two Podium Presentations On Bimatoprost Sustained-Release (SR) At The American Society Of Cataract And Refractive Surgery (ASCRS) Annual Meeting

-New data will provide insights on treatment duration and biodegradation of the experimental implant in patients with open-angle glaucoma or ocular hypertension-

Allergan Continues To Display Leadership In Neurosciences With 29 Presentations At 2019 American Academy Of Neurology Annual Meeting

Allergan Continues To Display Leadership In Neurosciences With 29 Presentations At 2019 American Academy Of Neurology Annual Meeting

- Allergan MIND™, Allergan's migraine franchise, leads meeting with the most migraine presentations: 24 abstracts highlighting BOTOX® (onabotulinumtoxinA) for Chronic Migraine, ubrogepant and atogepant -

What Goes Up: Cramer's 'Mad Money' Recap (Wednesday 5/1/19)

What Goes Up: Cramer's 'Mad Money' Recap (Wednesday 5/1/19)

Jim Cramer says it's not 1987 or 1999, and there's no reason to dump stocks right now, but he does advocate discipline and caution.

Kohl's, Exxon Mobil, Delta Air Lines: 'Mad Money' Lightning Round

Kohl's, Exxon Mobil, Delta Air Lines: 'Mad Money' Lightning Round

Jim Cramer weighs in on Kohl's, Exxon Mobil, Delta Air Lines, Allergan, Arrowhead Research, Wayfair, Varonis Systems and more.

Allergan Announces Results From The 2019 Annual General Meeting Of Shareholders

Allergan Announces Results From The 2019 Annual General Meeting Of Shareholders

-- Shareholders Approved All Allergan Proposals and Voted AGAINST Shareholder Proposal Calling for Immediate Separation of Chairman and CEO Role --

Breakthrough Tuesday

New highs grow on the New York Stock Exchange and the Investor Intelligence bulls finally tops 55%.

New Study Showcases Economic And Community Impact Of Allergan's Operations In Ohio

New Study Showcases Economic And Community Impact Of Allergan's Operations In Ohio

- Cincinnati facility generates annual economic output of $46.3 million and total earnings of $28.8 million -

Leading Proxy Advisory Firms ISS And Glass Lewis Support ALL Of Allergan Board's Voting Recommendations

Leading Proxy Advisory Firms ISS And Glass Lewis Support ALL Of Allergan Board's Voting Recommendations

- ISS and Glass Lewis Recommend AGAINST Appaloosa's Proposal to Immediately Separate Chair and CEO Roles -

Allergan Earns 2019 ENERGY STAR® Partner Of The Year - Sustained Excellence Award For The Sixth Consecutive Year

Allergan Earns 2019 ENERGY STAR® Partner Of The Year - Sustained Excellence Award For The Sixth Consecutive Year

- Company Recognized for Continued Superior Energy Achievements -

Allergan To Report First Quarter 2019 Financial Results And Host Conference Call And Webcast

Allergan To Report First Quarter 2019 Financial Results And Host Conference Call And Webcast

DUBLIN, April 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release first quarter 2019 financial results on Tuesday, May 7, 2019, prior to the open of U.

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Digital Boom and Millennials are Growing the Category, Wellness and Self-Care are New Key Drivers, Interest is in Eyes and Body Contouring

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Digital Boom and Millennials are Growing the Category, Wellness and Self-Care are New Key Drivers, Interest is in Eyes and Body Contouring

Aegon Publishes Agenda For 2019 Annual General Meeting

Aegon Publishes Agenda For 2019 Annual General Meeting

Today, Aegon N.V.

Allergan And Molecular Partners Announce Topline Safety Results From MAPLE Study Of Abicipar Pegol

Allergan And Molecular Partners Announce Topline Safety Results From MAPLE Study Of Abicipar Pegol

The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation

Aegon Prices EUR 500 Million Restricted Tier 1 Securities

Aegon Prices EUR 500 Million Restricted Tier 1 Securities

Today, Aegon successfully priced its inaugural EUR 500 million Restricted Tier 1 perpetual contingent convertible securities, with a fixed coupon of 5.

More Mud on Johnson & Johnson?

More Mud on Johnson & Johnson?

There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.

Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System To Best-in-Class Medical Aesthetics Portfolio

Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System To Best-in-Class Medical Aesthetics Portfolio

- Proprietary Skin Resurfacing Treatment for the Face and Body Reinforces Allergan's Commitment to Skin Quality -

Aegon Publishes 2018 Integrated Annual Report

Aegon Publishes 2018 Integrated Annual Report

Today, Aegon N.V.

CoolSculpting® And Sonja Morgan Partner To Talk Bikini Denial

CoolSculpting® And Sonja Morgan Partner To Talk Bikini Denial

-- Television Personality is Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --

Allergan Announces FDA Approval Of AVYCAZ® (ceftazidime And Avibactam) For Pediatric Patients

Allergan Announces FDA Approval Of AVYCAZ® (ceftazidime And Avibactam) For Pediatric Patients

- Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older -

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Allergan Announces FDA Acceptance Of New Drug Application For Ubrogepant For The Acute Treatment Of Migraine

Allergan Announces FDA Acceptance Of New Drug Application For Ubrogepant For The Acute Treatment Of Migraine

- Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine -

TheStreet Quant Rating: C (Hold)